MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
12 août 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
05 août 2024 08h00 HE
|
MBX Biosciences, Inc.
Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2...
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
25 juin 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., June 25, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
05 févr. 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
31 janv. 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
20 déc. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
15 nov. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
01 nov. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
31 oct. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
16 oct. 2023 16h00 HE
|
MBX Biosciences, Inc.
MBX 2109 was generally well-tolerated across all dosing cohorts MBX 2109 pharmacokinetics reflected the intended prodrug design and support once-weekly dosing MBX 2109 increased albumin adjusted...